PS-2020a / part16

DICOM PS3.16 2020a - Content Mapping Resource​

Page 1321​

Code Value​

Code Meaning​

Definition​

Notes​

See St. Lawrence KS, Lee T-Y. An Adiabatic​

Approximation to the Tissue Homogeneity Model for​

Water Exchange in the Brain: I. Theoretical Derivation.​

J Cereb Blood Flow Metab. 1998 Dec;18(12):1365-77.​

doi:10.1097/00004647-199812000-00011.​

126347​

Two Compartment Exchange​ A tracer diffusion kinetic that incorporates the​

(2CX) Model​

extracellular space of the lesion as a peripheral​

compartment, connected to the central (plasma)​

compartment by linear exchange processes in both​

directions.​

See Brix G, Semmler W, Port R, Schad LR, Layer G,​

Lorenz WJ. Pharmacokinetic Parameters in CNS​

Gd-DTPA Enhanced MR Imaging. Journal of Computer​

Assisted Tomography. 1991;15(4):621-8.​

126350​

T1 by Multiple Flip Angles​

T1measurementbyMultipleFlipAngles(MFA)(variable​

saturation) method​

126351​

T1 by Inversion Recovery​

T1 measurement by Inversion Recovery (IR) method​

126352​

T1 by Fixed Value​

Calculation was performed using a fixed value of T1​

rather than a measured value. The value could be​

encoded as the value of (126353, DCM, "T1 Used For​

Calculation").​

126353​

T1 Used For Calculation​

The fixed value of T1 used for a calculation.​

126360​

AIF Ignored​

No Arterial Input Function was used.​

126361​

Population Averaged AIF​

A population-averaged Arterial Input Function.​

126362​

User-defined AIF ROI​

AnArterialInputFunctioncomputedfromauser-defined​

Region of Interest.​

126363​ AutomaticallyDetectedAIFROI​An Arterial Input Function computed from an​

automatically detected Region of Interest.​

126364​

Blind Estimation of AIF​

A data-driven blind source separation (BSS) algorithm​

thatestimatesAIFfromindividualswithoutanypresumed​

AIF model and initialization. See Lin, Yu-Chun,​

Tsung-Han Chan, Chong-Yung Chi, Shu-Hang Ng,​

Hao-Li Liu, Kuo-Chen Wei, Yau-Yau Wai, Chun-Chieh​

Wang, and Jiun-Jie Wang. "Blind Estimation of the​

Arterial Input Function in Dynamic Contrast-Enhanced​

MRI Using Purity Maximization." Magnetic Resonance​

in Medicine 68, no. 5 (November 1, 2012): 1439-49.​

doi:10.1002/mrm.24144.​

126370​

Time of Peak Concentration​

Thetimeatwhichtheconcentration-timecurveachieves​

its peak for the first time. Used as a concept name for a​

value or as a method. E.g., used as a method of​

calculation for BAT. See Shpilfoygel Med Phys 2008.​

doi:10.1118/1.1288669.​

Page 1322​

DICOM PS3.16 2020a - Content Mapping Resource​

Code Value​

Code Meaning​

Definition​

Notes​

126371​

Bolus Arrival Time​

The nominal time at which arrival of a contrast bolus is​

detected, which is used as a reference point for​

subsequent calculations. Used as a concept name for a​

valueorasamethod.Nospecificcomputationalmethod​

is implied by this general definition. Abbreviated BAT.​

126372​ Time of Leading Half-Peak​

Thetimeatwhichtheconcentration-timecurveachieves​

Concentration​

half of its peak density for the first time. Used as a​

concept name for a value or as a method. E.g., used as​

a method of calculation for BAT. See Shpilfoygel Med​

Phys 2008. doi:10.1118/1.1288669.​

126373​ Temporal Derivative Exceeds​ A method of determining BAT that involves computing​

Threshold​

the temporal derivative of the concentration-time curve​

and selecting the time when the temporal derivative​

exceedsaspecifiedthreshold.SeeShpilfoygelMedPhys​

2008. doi:10.1118/1.1288669.​

126374​ Temporal Derivative Threshold​A threshold applied to the temporal derivative of the​

concentration-time curve. E.g., used to establish BAT.​

SeeShpilfoygelMedPhys2008.doi:10.1118/1.1288669.​

126375​

Maximum Slope​

The maximum rate of signal intensity change within a​

measured region of a time-activity curve. See​

Boonsirikamchai, Piyaporn, Harmeet Kaur, Deborah A.​

Kuban, Edward Jackson, Ping Hou, and Haesun Choi.​

"Use of Maximum Slope Images Generated From​

Dynamic Contrast-Enhanced MRI to Detect Locally​

Recurrent Prostate Carcinoma After Prostatectomy: A​

PracticalApproach."AmericanJournalofRoentgenology​

198, no. 3 (March 1, 2012): W228-W236.​

doi:10.2214/AJR.10.6387.​

126376​

Maximum Difference​

The maximum degree of signal intensity change within​

a measured region of a time-activity curve. See​

Boonsirikamchai, Piyaporn, Harmeet Kaur, Deborah A.​

Kuban, Edward Jackson, Ping Hou, and Haesun Choi.​

"Use of Maximum Slope Images Generated From​

Dynamic Contrast-Enhanced MRI to Detect Locally​

Recurrent Prostate Carcinoma After Prostatectomy: A​

PracticalApproach."AmericanJournalofRoentgenology​

198, no. 3 (March 1, 2012): W228-W236.​

doi:10.2214/AJR.10.6387.​

126377​

Tracer Concentration​

Tracer concentration in tissue. E.g., in a DCE-MR​

experiment,theconcentrationofcontrastagentinmmol/l.​

126380​ Contrast Longitudinal Relaxivity​The degree to which a paramagnetic contrast agent can​

enhance the proton longitudinal relaxation rate constant​

(R1,1/T1),normalizedtotheconcentrationofthecontrast​

agent.Alsoreferredtoasr1.Typicallyexpressedinunits​

of l/mmol/s.​

126390​ Absolute Regional Blood Flow​The absolute flow rate of blood perfusing a region as​

volume per mass per unit of time. The mass divisor may​

beapproximatedbyameasurementofvolumeassuming​

a tissue density of 1.​

126391​

AbsoluteRegionalBloodVolume​The absolute volume of blood perfusing a region as​

volumepermass.Themassdivisormaybeapproximated​

by a measurement of volume assuming a tissue density​

of 1.​

Page 1324​

DICOM PS3.16 2020a - Content Mapping Resource​

Code Value​

Code Meaning​

Definition​

Notes​

126401​

SUVbw​

StandardizedUptakeValuecalculatedusingbodyweight.​

The patient size correction factor for males and females​

is body weight.​

Defined in Sugawara et al. Reevaluation of the​

Standardized Uptake Value for FDG: Variations with​

Body Weight and Methods for Correction.Radiology,​

1999 at http://radiology.rsna.org/content/213/2/521​

126402​

SUVlbm​

Standardized Uptake Value calculated using lean body​

massbyJamesmethod.Thepatientsizecorrectionfactor​

for males is 1.10 * weight - (120 or 128) * (weight/height)​

^2,andforfemalesis1.07*weight-148*(weight/height)​

^2.​

Defined in Sugawara et al. Reevaluation of the​

Standardized Uptake Value for FDG: Variations with​

Body Weight and Methods for Correction.Radiology,​

1999 at http://radiology.rsna.org/content/213/2/521,​

except that either 120 or 128 may be used as the​

multiplier parameter for males).​

Unfortunately,Sugawarausedaparameterof120rather​

than 128, propagating an error in Morgan DJ, Bray KM.​

Lean Body Mass as a Predictor of Drug Dosage:​

ImplicationsforDrugTherapy.ClinicalPharmacokinetics.​

1994;26(4):292-307, which misquoted the original LBM​

definition that used 128 in James WPT, Waterlow JC.​

ResearchonObesity:AReportoftheDHSS/MRCGroup.​

London: Her Majesty’s Stationery Office; 1976.​

Implementations differ in whether they have used 120​

or 128 when using this code. See Kelly M. SUV:​

AdvancingComparabilityandAccuracy.Siemens;2009.​

Availablefrom:http://www.mpcphysics.com/documents/​

SUV_Whitepaper_Final_11.17.09_59807428_2.pdf.​

126403​

SUVbsa​

StandardizedUptakeValuecalculatedusingbodysurface​

area. The patient size correction factor for males and​

females is weight^ 0.425 * height^0.725 * 0.007184.​

Defined in Sugawara et al. Reevaluation of the​

Standardized Uptake Value for FDG: Variations with​

Body Weight and Methods for Correction.Radiology,​

1999 at http://radiology.rsna.org/content/213/2/521​

126404​

SUVibw​

Standardized Uptake Value calculated using ideal body​

weight. The patient size correction factor for males is​

48.0+1.06*(height-152)andforfemalesis45.5+0.91​

* (height - 152).​

Defined in Janmahasatian et al. Quantification of Lean​

Bodyweight. Clin Pharmacokinet. 2005 Oct​

1;44(10):1051-65. at http://dx.doi.org/10.2165/​

00003088-200544100-00004 and its role in​

SUVlbm(Janma) calculation is discussed in Tahari et al.​

Optimum Lean Body Formulation for Correction of​

Standardized Uptake Value in PET Imaging. Journal of​

Nuclear Medicine. 2014 Sep 1;55(9):1481-4. at http://​

jnm.snmjournals.org/content/55/9/1481.​

126406​ SUVlbm(James128)​

Standardized Uptake Value calculated using lean body​

mass by James method, using the originally published​

128multiplierformales.Thepatientsizecorrectionfactor​

formalesis1.10*weight-128)*(weight/height)^2,and​

for females is 1.07 * weight - 148 * (weight/height) ^2.​

Page 1326​

DICOM PS3.16 2020a - Content Mapping Resource​

Code Value​

Code Meaning​

Definition​

Notes​

126412​

SUV body surface area​

Method of calculating Standardized Uptake Value using​

calculation method​

body surface area. The patient size correction factor for​

males and females is weight^ 0.425 * height^0.725 *​

0.007184.​

Defined in Sugawara et al. Reevaluation of the​

Standardized Uptake Value for FDG: Variations with​

Body Weight and Methods for Correction.Radiology,​

1999 at http://radiology.rsna.org/content/213/2/521​

126413​ SUV ideal body weight​

Method of calculating Standardized Uptake Value using​

calculation method​

ideal body weight. The patient size correction factor for​

males is 48.0 + 1.06 * (height - 152) and for females is​

45.5 + 0.91 * (height - 152).​

Defined in Sugawara et al. Reevaluation of the​

Standardized Uptake Value for FDG: Variations with​

Body Weight and Methods for Correction.Radiology,​

1999 at http://radiology.rsna.org/content/213/2/521​

Janmahasatian method​

Uptake Value using lean body mass. The patient size​

correction factor for males is 9.27E3 * weight / (6.68E3​

+ 216 * weight / (height^2)) and for females is 9.27E3 *​

weight / (8.78E3 + 244 * weight / (height^2)).​

Defined in Janmahasatian et al. Quantification of Lean​

Bodyweight. Clin Pharmacokinet. 2005 Oct​

1;44(10):1051-65. at http://dx.doi.org/10.2165/​

00003088-200544100-00004 and its role in​

SUVlbm(Janma) calculation is discussed in Tahari et al.​

Optimum Lean Body Formulation for Correction of​

Standardized Uptake Value in PET Imaging. Journal of​

Nuclear Medicine. 2014 Sep 1;55(9):1481-4. at http://​

jnm.snmjournals.org/content/55/9/1481.​

method using 128 multiplier​

using lean body mass with the originally published 128​

multiplierformales.Thepatientsizecorrectionfactorfor​

males is 1.10 * weight - 128) * (weight/height) ^2, and​

for females is 1.07 * weight - 148 * (weight/height) ^2.​

thioflavin T.​

126501​

Florbetaben F^18^​

A beta-amyloid PET radiotracer.​

126502​

T807 F^18^​

A PHF-tau PET radiotracer.​

126503​

Flubatine F^18^​

A nicotinic α4β2 receptor (nAChR) PET radiotracer.​

126510​

Monoclonal Antibody (mAb)​

A Cu 64 Monoclonal Antibody (mAb) PET Radiotracer.​

^64^Cu​

126511​

Monoclonal Antibody (mAb)​

A Zr 89 Monoclonal Antibody (mAb) PET Radiotracer.​

^89^Zr​

126512​

Trastuzumab ^89^Zr​

A Zr 89

Trastuzumab PET Radiotracer.​

126513​

Cetuximab ^89^Zr​

A Zr 89

Cetuximab PET Radiotracer.​

126514​

J591 ^89^Zr​

A Zr 89

J591 PET Radiotracer.​

126515​

cU36 ^89^Zr​

A Zr 89 cU36 PET Radiotracer.​

126516​

Bevacizumab ^89^Zr​

A Zr 89

Bevacizumab PET Radiotracer.​

DICOM PS3.16 2020a - Content Mapping Resource​

Page 1327​

Code Value​

Code Meaning​

Definition​

Notes​

126517​

cG250-F(ab')(2) ^89^Zr​

A Zr 89 cG250-F(ab')(2) PET Radiotracer.​

126518​

R1507 ^89^Zr​

A Zr 89 R1507 PET Radiotracer.​

126519​

E4G10 ^89^Zr​

A Zr 89 E4G10 PET Radiotracer.​

126520​

Df-CD45 ^89^Zr​

A Zr 89 Df-CD45 PET Radiotracer.​

126600​

^44^Scandium​

^44^Scandium​

126601​

^51^Manganese​

^51^Manganese​

126602​

^70^Arsenic​

^70^Arsenic​

126603​

^90^Niobium​

^90^Niobium​

126604​

^191m^Iridium​

^191m^Iridium​

126605​

^43^Scandium​

^43^Scandium​

126606​

^152^Terbium​

^152^Terbium​

126607​

^52m^Manganese​

^52m^Manganese​

126700​

ATSM Cu^60^​

A Cu 60 ATSM PET radiotracer.​

126701​

ATSM Cu^61^​

A Cu 61 ATSM PET radiotracer.​

126702​

ATSM Cu^62^​

A Cu 62 ATSM PET radiotracer.​

126703​

Choline C^11^​

A C 11 Choline PET radiotracer.​

126704​

Fallypride C^11^​

A C 11 Fallypride PET radiotracer.​

126705​

Fallypride F^18^​

An F 18 Fallypride PET radiotracer.​

126706​

FLB 457 C^11^​

A C 11 FLB 457 PET radiotracer.​

126707​

Fluorotriopride F^18^​

An F 18 Fluorotriopride PET radiotracer.​

126708​

Fluoromisonidazole (FMISO)​

An F 18 Fluoromisonidazole PET radiotracer.​

F^18^​

126709​

Glutamine C^11^​

A C 11 Glutamine PET radiotracer.​

126710​

Glutamine C^14^​

A C 14 Glutamine PET radiotracer.​

126711​

Glutamine F^18^​

An F 18 Glutamine PET radiotracer.​

126712​

Flubatine F^18^​

An F 18 Flubatine PET radiotracer.​

Retired.​

Replacedwith(126503,DCM,​

"Flubatine F^18^").​

126713​

2FA F^18^​

An F 18 2FA PET radiotracer.​

126714​

Nifene F^18^​

An F 18 Nifene PET radiotracer.​

126715​

CLR1404 I^124^​

An I 124 cancer targeted phospholipid ether PET​

radiotracer.​

126716​

CLR1404 I^131^​

An I 131 cancer targeted phospholipid ether PET​

radiotracer.​

126717​

THK5351 F^18^​

A PET radiotracer used for tau brain imaging.​

Retired.​

Page 1328​

DICOM PS3.16 2020a - Content Mapping Resource​

Code Value​

Code Meaning​

Definition​

Notes​

126718​

Flurpiridaz F^18^​

APETradiotracerusedformyocardialperfusionimaging.​

SeeYuM,NekollaSG,SchwaigerM,RobinsonSP.The​

Next Generation of Cardiac Positron Emission​

Tomography Imaging Agents: Discovery of Flurpiridaz​

F-18 for Detection of Coronary Disease. Seminars in​

Nuclear Medicine. 2011 Jul;41(4):305-13.​

doi:10.1053/j.semnuclmed.2011.02.004​

SeeSNMMI.Flurpiridaz.http://interactive.snm.org/docs/​

PET_PROS/flurpiridaz_%2007_30_12_Final.pdf​

126719​

RO6924963 ^11^C​

A PET radiotracer used for tau brain imaging.​

See Wong DF, Comley R, Kuwabara H, Rosenberg PB,​

Resnick SM, Ostrowitzki S, et al. First in-human PET​

study of 3 novel tau radiopharmaceuticals:​

[11C]RO6924963, [11C]RO6931643, and​

[18F]RO6958948. J Nucl Med. 2018 May 4;​

doi:10.2967/jnumed.118.209916. http://​

jnm.snmjournals.org/content/early/2018/05/03/​

jnumed.118.209916​

126720​

RO6931643 ^11^C​

A PET radiotracer used for tau brain imaging.​

126721​

Obinituzimab ^89^Zr​

A Zr 89

Obinituzimab PET Radiotracer.​

126722​

Benralizumab ^89^Zr​

A Zr 89

Benralizumab PET Radiotracer.​

126723​

Ocaratuzumab ^89^Zr​

A Zr 89

Ocaratuzumab PET Radiotracer.​

126724​

Glembatumumabvedotin^89^Zr​A Zr 89

Glembatumumab vedotin PET Radiotracer.​

126725​

Pinatuzumab vedotin ^89^Zr​

A Zr 89

Pinatuzumab vedotin PET Radiotracer.​

126726​

Polatuzumab vedotin ^89^Zr​

A Zr 89

Polatuzumab vedotin PET Radiotracer.​

126727​

Blinatumomab ^89^Zr​

A Zr 89

Blinatumomab PET Radiotracer.​

126728​

Pegdinetanib ^89^Zr​

A Zr 89

Pegdinetanib PET Radiotracer.​

126729​

AGN-150998 ^89^Zr​

A Zr 89 AGN-150998 PET Radiotracer.​

126730​

MEDI-551 ^89^Zr​

A Zr 89 MEDI-551 PET Radiotracer.​

126731​

GA201 ^89^Zr​

A Zr 89 GA201 PET Radiotracer.​

126732​

Ecromeximab ^89^Zr​

A Zr 89 Ecromeximab PET Radiotracer.​

126733​

Roledumab ^89^Zr​

A Zr 89 Roledumab PET Radiotracer.​

126734​

XmAb5574 ^89^Zr​

A Zr 89 XmAb5574 PET Radiotracer.​

126735​

Brentuximab ^89^Zr​

A Zr 89

Brentuximab PET Radiotracer.​

126736​

Panitumumab ^89^Zr​

A Zr 89 Panitumumab PET Radiotracer.​

126737​

Rituximab ^89^Zr​

A Zr 89

Rituximab PET Radiotracer.​

126738​

Mogamulizumab ^89^Zr​

A Zr 89 Mogamulizumab PET Radiotracer.​

126739​

Ublituximab ^89^Zr​

A Zr 89

Ublituximab PET Radiotracer.​

Page 1330​

DICOM PS3.16 2020a - Content Mapping Resource​

Code Value​

Code Meaning​

Definition​

Notes​

126760​

Df-FK ^89^Zr​

A Zr 89 Df-FK peptide PET Radiotracer.​

SeeJacobsenOetal.MicroPETImagingofIntegrinαvβ3​

Expressing Tumors Using 89Zr-RGD Peptides. Mol​

Imaging Biol. 2011 Dec; 13(6): 1224-1233.​

doi:10.1007/s11307-010-0458-y.​

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137711/​

126761​

Df-FK-PEG(3) ^89^Zr​

A Zr 89 Df-FK-PEG(3) peptide PET Radiotracer.​

SeeJacobsenOetal.MicroPETImagingofIntegrinαvβ3​

Expressing Tumors Using 89Zr-RGD Peptides. Mol​

Imaging Biol. 2011 Dec; 13(6): 1224-1233.​

doi:10.1007/s11307-010-0458-y.​

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137711/​

126762​

Df-[FK](2) ^89^Zr​

A Zr 89 Df-[FK](2) peptide PET Radiotracer.​

SeeJacobsenOetal.MicroPETImagingofIntegrinαvβ3​

Expressing Tumors Using 89Zr-RGD Peptides. Mol​

Imaging Biol. 2011 Dec; 13(6): 1224-1233.​

doi:10.1007/s11307-010-0458-y.​

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137711/​

126763​

Df-[FK](2)-3PEG(4) ^89^Zr​

A Zr 89 Df-[FK](2)-3PEG(4) peptide PET Radiotracer.​

SeeJacobsenOetal.MicroPETImagingofIntegrinαvβ3​

Expressing Tumors Using 89Zr-RGD Peptides. Mol​

Imaging Biol. 2011 Dec; 13(6): 1224-1233.​

doi:10.1007/s11307-010-0458-y.​

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137711/​

126764​

Iodinated I^125^ DPA-713​

An I125 translocator protein (TSPO) SPECT tracer.​

See Wang H, Pullambhatla M, Guilarte TR, Mease RC,​

Pomper MG. Synthesis of [125I]IodoDPA-713, a New​

Probe for Imaging Inflammation. Biochem Biophys Res​

Commun.2009Nov6;389(1):80–3.doi:10.1007/10.1016/​

j.bbrc.2009.08.102 http://www.ncbi.nlm.nih.gov/pmc/​

articles/PMC2764231/​

126765​

DPA-713 ^11^C​

A C11 translocator protein (TSPO) PET tracer.​

See Endres CJ, Pomper MG, James M, Uzuner O,​

Hammoud DA, Watkins CC, et al. Initial Evaluation of​

11C-DPA-713, a Novel TSPO PET Ligand, in Humans.​

J Nucl Med. 2009 Aug;50(8):1276–82. doi:10.2967/​

jnumed.109.062265 http://www.ncbi.nlm.nih.gov/pmc/​

articles/PMC2883612/​

126766​

DPA-714 ^18^F​

An F18 translocator protein (TSPO) PET tracer.​

See Vicidomini C, Panico M, Greco A, Gargiulo S, Coda​

ARD, Zannetti A, et al. In vivo imaging and​

characterizationof[18F]DPA-714,apotentialnewTSPO​

ligand, in mouse brain and peripheral tissues using​

small-animal PET. Nuclear Medicine and Biology. 2015​